Our Financial
Performance

Marion McCourt, Executive Vice President, Head of Commercial: Bob, let's talk about business performance in 2021.

Robert (Bob) Landry, Executive Vice President, Finance & CFO: Yeah, I mean, as we now go into 2022, I mean, it was just a fantastic year across the board. I think revenue of something like $16 billion coming off of a base of, I don't know, eight and a half billion in 2020. It was fantastic. Now people will say, "Well Bob, you had REGEN-COV." And even if you take all that away and just look at the core business, we still grew 22%. Which, I mean, that puts us kind of in the top decile of high growth companies, it's really quite an achievement.

Marion: Really, the bringing of REGEN-COV to the marketplace for Regeneron, I'll start with that, was just such a remarkable application of our science and technology built over 30 years. And to be able to bring the pride all of our employees feel in being able to help with so many patients during the pandemic period. But on the global scale, the collaboration with Roche, it allowed us to extend our manufacturing, potentially have more supply availability, and get them to prescribers and patients in need.

Bob: Marion, we all have watershed moments in our life. And I think 2021, for me, will go down with regards to working for a company that has life saving medicines and that actually put that to unbelievable use in the midst of a world pandemic.

Marion: I mean, I give credit to our teams that even in a pandemic year, we're able to turn in such noteworthy performance. And from a business performance, financial perspective, the best in our company's history, in difficult times. But I'd say, when I look at it now and with greatest pride, the diversification of our portfolio, obviously taking Eylea, our flagship product to new heights. Better than ever before in terms of percentage growth performance. For 10 year old product to grow by 17% is absolutely remarkable.

Bob: Yeah, I think for the longest time, and you know this better than me, I mean, we've been known as kind of the eye company. But now as we get new products, whether they be Evkeeza that got off to a nice start, certainly Libtayo continues to grow globally. And then Dupixent and all the indications that keep coming. I think our investor base and our shareholders know that we are a very, very diverse company. So Marion, you and I have been spending a lot of time with regards to global expansion and global footprint.

Marion: So this past year, to the thanks of not only the commercial organization, but our colleagues, Bob and your team, finance, IT, all the G&A functions we've set up operations for Sales Force activity in Germany, Netherlands, UK, and Canada.

Bob: You know, it really sets us up, and I think our investor base, looking at everything we have in R&D, in the growth that we achieved from our core business, has really set us up for the future to be just kind of guns blazing. In 2022, what are you most excited about?

Marion: I'm incredibly excited about bringing all of our great people together again and the energy that comes from that. And I can't help but say many companies don't have a single product that is the level of blockbuster success that we have with Eylea and now Dupixent. We have two and more coming and we have such rich science at Regeneron. It's why we're here. And it really reminds me that I don't get occasion to thank my team as often as I should all together, so maybe just a quick shout out to everybody in the commercial organization of the pride and the personal thanks I have to each of you and our teams for doing such a great job every day.